Novartis to present data from Phase 3 ASC4FIRST study at ASCO and EHA

Novartis will present data from more than 60 abstracts, including investigator-initiated trials at the 2024 American Society of Clinical Oncology, or ASCO, Annual Meeting and the European Hematology Association, or EHA, 2024 Hybrid Congress, the company announced. The primary results from ASC4FIRST, a pivotal Phase III study of Scemblix versus standard of care tyrosine kinase inhibitors in newly diagnosed patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase will be shared at the ASCO official Press Program and at the EHA Plenary Session, the company noted. “We look forward to sharing the primary analysis from the pivotal Phase III ASC4FIRST trial, which builds on our over 20-year legacy to transform care for people diagnosed with CML. With these promising data, a new analysis of the NATALEE trial in patients with node-negative early breast cancer and additional updates from our RLT portfolio, we further our efforts to reimagine medicine for those with cancer in partnership with the scientific community,” said Jeff Legos, Executive Vice President, Global Head of Oncology, Novartis.